Eurofins Scientific stock analysis
Eurofins Scientific (0MV5) Share Price & Analysis
0MV5 Stock Chart & Stats
- Day’s Range
- EUR 87.56 - EUR 88.46
- 52-Week Range
- EUR 56.24 - EUR 89.24
- Previous Close
- EUR 88.00
- Volume
- N/A
- Average Volume (3M)
- 66.67K
- Market Cap
- EUR 15.49B
- Enterprise Value
- EUR 17.48B
- Total Cash (Recent Filing)
- EUR 618.00M
- Total Debt (Recent Filing)
- EUR 5.47B
- Price to Earnings (P/E)
- 29.3
- Beta
- 0.95
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- 1.61
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.82%
Bulls Say, Bears Say
Bulls Say
Diversified Laboratory Services Platform
Eurofins operates across multiple testing end markets and serves corporate and public-sector clients, creating a broad revenue base. This diversification can support resilience because demand is not tied to one scientific application, customer group, or industry cycle, while its wide laboratory network enables a broad service offering.
Strong 2025 Revenue Growth
The sharp 2025 revenue expansion indicates renewed commercial momentum after a weaker multi-year period. If sustained, higher volume across Eurofins’ testing businesses can improve laboratory utilization, broaden customer relationships, and provide a stronger base for earnings growth over the next several quarters.
Positive Operating Cash Generation
Operating cash flow of approximately €1.30B demonstrates that Eurofins’ laboratory services generate substantial cash from ongoing operations. This provides internal funding for capital investment, debt service, and business development, even though the weaker free-cash-flow conversion means the quality of that cash generation requires monitoring.
Bears Say
Material Increase In Leverage
The substantial increase in debt relative to equity has reduced Eurofins’ balance-sheet flexibility. A higher debt load can increase refinancing and interest-burden exposure if operating performance weakens, while also limiting the company’s ability to fund acquisitions, investment, or shareholder returns without additional financial pressure.
Weaker Free-cash-flow Conversion
Free cash flow declined despite stronger reported revenue and profits, and conversion fell to about 41% of net income from roughly 60% in 2024. This indicates that capital spending or working-capital needs are absorbing more earnings, reducing internally available funds and weakening cash-flow quality.
Deteriorating Profit-margin Quality
The long-term decline in net margin suggests that revenue growth has not translated proportionally into bottom-line profitability. The unusually low 2025 gross margin also creates uncertainty around the cost structure or one-off effects, making sustained earnings quality and margin recovery less certain.
Eurofins Scientific News
0MV5 FAQ
What was Eurofins Scientific’s price range in the past 12 months?
What is Eurofins Scientific’s market cap?
When is Eurofins Scientific’s upcoming earnings report date?
How were Eurofins Scientific’s earnings last quarter?
Is Eurofins Scientific overvalued?
Does Eurofins Scientific pay dividends?
What is Eurofins Scientific’s EPS estimate?
How many shares outstanding does Eurofins Scientific have?
What happened to Eurofins Scientific’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Eurofins Scientific?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Eurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
- Sector
- General
- Industry
- Medical - Diagnostics & Research
- CEO
- Gilles G. Martin
- Employees
- 65,000
- Website
- www.eurofins.com
- Address
- 23 Val Fleuri, Luxembourg City, LU, 1526, LU
Eurofins Scientific (0MV5) Earnings & Revenues
0MV5 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 9 | 0 | 3 |
